肝移植后炎症性肠病患者使用全身性生物制剂与维得利珠单抗的安全性相似
这项回顾性双中心研究纳入2001至2023年间肝移植后接受生物制剂治疗的36例炎症性肠病患者,共59个生物制剂暴露疗程。结果显示,肠道特异性生物制剂(维得利珠单抗)与全身性生物制剂(抗TNF/乌司奴单抗)的感染事件发生率无显著差异(0.43 vs 0.50/患者年,IRR 1.09,95%CI 0.58-2.02,p=0.79)。生物制剂启动时使用糖皮质激素是唯一与严重感染事件相关的非生物制剂免疫抑制剂(IRR 5.40,95%CI 1.66-17.63,p<0.01)。
要点
- 肝移植后IBD患者中,肠道特异性与全身性生物制剂的感染事件发生率无显著差异。
- 生物制剂启动时使用糖皮质激素与更严重的感染事件相关(IRR 5.40)。
- 生物制剂选择不应受移植免疫抑制联合用药担忧的影响。
核心结论
- 肝移植后IBD患者使用肠道特异性与全身性生物制剂的感染事件发生率相似。
- 生物制剂选择不应受与移植免疫抑制联合处方的担忧影响。
- 生物制剂启动时糖皮质激素联合治疗可能与更严重的感染事件相关。
研究设计与样本
- 回顾性双中心研究,纳入2001年至2023年间肝移植后接受生物制剂治疗的炎症性肠病患者。
- 共36例患者,59个生物制剂暴露疗程(中位12个月,IQR 6-27)。
主要发现
- 肠道特异性生物制剂(维得利珠单抗27个疗程,45.7%)与全身性生物制剂(抗TNF 22个疗程,37.2%;乌司奴单抗10个疗程,16.9%)分别累计暴露44.5和44.4患者年。
- 27个(45.7%)生物制剂疗程与41次感染事件相关,中位发生在生物制剂启动后8个月(IQR 4.5-13.5)。
- 肠道特异性与全身性生物制剂的感染事件发生率无显著差异(0.43 vs 0.50/患者年,IRR 1.09,95%CI 0.58-2.02,p=0.79)。
- 生物制剂启动时使用糖皮质激素是唯一与严重感染事件相关的非生物制剂免疫抑制剂(IRR 5.40,95%CI 1.66-17.63,p<0.01)。
临床怎么用
- 作者认为,生物制剂选择不应受与移植免疫抑制联合处方的担忧影响。
- 作者指出,生物制剂启动时糖皮质激素联合治疗可能与更严重的感染事件相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: 'Gut-specific' biologics are associated with fewer infectious complications than 'systemic' biologics in inflammatory bowel disease (IBD) which represents an important consideration in transplant recipients. This study evaluated the safety of combining transplant immunosuppression with 'gut-specific' versus 'systemic' biologics to manage IBD following liver transplantation (LTx). METHODS: A retrospective dual-centre study of IBD patients exposed to biologics following LTx between 2001 and 2023 was undertaken. Primary outcome was the incidence rate of infectious events per patient-year of biologic exposure. Infectious events were stratified by 'gut-specific' (vedolizumab) and 'systemic' (anti-TNF/ustekinumab) biologic exposure with severe events defined by hospitalisation. Secondary outcomes included the impact of non-biologic immunosuppression on the incidence of infectious and non-infectious complications. RESULTS: Thirty-six IBD patients were exposed to 59 (median 12 [IQR 6-27] months) biologic episodes following LTx. Patients were collectively exposed to 44.5 and 44.4 patient-years of 'gut-specific' (vedolizumab = 27 [45.7%]) and 'systemic' (anti-TNF = 22 [37.2%]; ustekinumab = 10 [16.9%]) biologics, respectively. Twenty-seven (45.7%) biologic episodes were associated with 41 infectious events, a median of 8 months (IQR 4.5-13.5) following biologic initiation. Rates of infectious events were not significantly different between 'gut-specific' and 'systemic' biologic exposures (0.43 vs. 0.50 per patient-year, incidence rate ratio [IRR] 1.09 [95% CI 0.58-2.02, p = 0.79]). Corticosteroid exposure at biologic initiation was the only non-biologic immunosuppressant associated with severe infectious events (IRR 5.40 [95% CI 1.66-17.63, p < 0.01]). CONCLUSION: Incidence of infectious events observed between IBD/LTx patients exposed to 'gut-specific' and 'systemic' biologics were similar. Biologic choice should not be influenced by concerns regarding their co-prescription with transplant immunosuppression. Corticosteroid co-therapy at biologic initiation may be associated with more severe infectious events.
引用
- Chin S, Con D, Hilley P, et al. Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation. Aliment Pharmacol Ther. 2025. PMID: 40663036. doi:10.1111/apt.70283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。